UK Government Minister Launches Impact Data Metrics Report

Sheffield, 16th July 2015 – Mapping Innovation Report released.

Today, the UK Minister of State for Universities and Science, Jo Johnson MP,  announced the publication of ‘Mapping Local Comparative Advantage in Innovation’ when he spoke at the University of Sheffield’s Advanced Manufacturing Research Centre. The main theme of his speech was the UK Government’s commitment to boost collaboration between business and universities as part of a bold and ambitious plan called One Science Nation.

2Bio’s Impact Data Metrics team, are co-authors of ‘Mapping Local Comparative Advantage in Innovation’ together with partners at the European Institute for Urban Affairs. This research has established a comprehensive framework for innovation indicators, and using the Impact Data Metrics platform, has added new datasets for the UK’s Local Economic Partnerships (LEPs) to build their future innovation strategies upon.

Geoff Wainwright of Impact Data Metrics said, “This was a fascinating piece of work to undertake and we were fortunate enough to work with a great team from the European Institute of Urban Affairs at Liverpool John Moores University, as well as colleagues from UK Departmernt of Business, Innovation & Skills. We analysed hundreds of thousands of data points to build very accurate and comprehensive maps of research, business and innovation activity across LEPs. This data is now finding real practical applications in providing detailed intelligence to support the building of plans for business growth, partnering and inward investment, and identifying key infrastructure requirements to support each LEP in understanding their innovation landscape and using this knowledge to realise their full growth potential. The range, depth and quality of the research activity we discovered was awe inspiring, and whilst we were only able to publish a high-level view of the data, we have continued to review, and keep current, the deep detail in the records for each LEP. We are seeing relationships and opportunities that will provide valuable starting points for analysis and planning. We are describing the knowledge economy of these areas in the same way as consumer activity is tracked.”

For more information on the capability of the Impact Data Metrics Platform, please contact:

Dr Geoff Wainwright
Tel. +44 (0)151 795 4100

For details of the Minister’s speech, please see:

To access the report, please see:


NIHR invites medtech companies to apply for Invention 4 Innovation (i4i) funding

The National Institute for Health Research (NIHR) invites applications to its Invention for Innovation (i4i) Programme. There are two types of award: Product Development awards and Challenge awards.

The NIHR is the research arm of the NHS and funds these awards for companies to develop R&D plans in collaboration with a university or an NHS organisation.

Product Development awards support R&D of medical devices, active implantable devices and in vitro diagnostic devices. Lead applicants may be from academia, industry or an NHS organisation and must be based in England or Wales. Calls are repeated two times per year.

For more, see:

Challenge awards are based on themed calls in areas of existing or emerging healthcare need. Lead applicants must be from NHS organisations in England and Wales and form partnerships with UK universities and/or companies based and conducting R&D in the UK. The themes will be repeated in autumn. The current themes are:

  • 􏰀  Oncology Diagnostics
  • 􏰀  Trauma and Critical Care.

For more, see

The deadline for outline applications for all calls is Wednesday 27 May 2015 1:00 pm.

To clarify whether your project is within scope or for any other questions , e-mail

To apply, visit:

Job Opportunity: Innovation & IP Manager

Innovation & IP Manager for the Healthcare Sector, based in Liverpool, UK.

2Bio Ltd. is seeking a highly motivated individual for the role of Innovation & IP Manager within our Impact Science Team, which provides innovation and commercialisation support to hospitals, universities, research organisations and private technology-based companies.

In this role you will use your expert knowledge to directly support the evaluation, development, and implementation of our client’s innovative ideas and inventions, and explore their commercialisation and protection when appropriate. You will deliver innovation support to an established portfolio of clients, working with a high degree of independence, and you will be encouraged to help grow the portfolio in both scale and scope. You will be working with a diverse range of UK and international clients.

We are a successful independent consultancy based in the North West of England, and have a proven track record of delivering commercialisation support – specialising in the life sciences and healthcare sectors, and their associated technology areas, including Pharmaceuticals, Biotechnology, Medical Devices & Diagnostics, IT & Software, and Healthcare Systems.

We are a dynamic company, and value both self-starters and team players, who can take responsibility and demonstrate the flexibility needed to deliver a high-quality service to our clients, anticipating their needs whenever possible and producing exceptional levels of client satisfaction. High performance in this role will be recognised with rapid advancement and enhanced rewards.

 About you:

You will have a University honours degree in a science/health subject and with at least a 2.1 grade, ideally you should also have a higher degree.

You will have an interest in the healthcare sector, and an understanding of the role that innovation and technology plays in its good functioning.

With informal training provided ‘on the job’, you will quickly be capable of performing evaluations of intellectual property (and other innovation assets) including their technical and commercial merits.

You should be able to engage confidently and sympathetically with our clients’ innovators and inventors, and ideally you will have a robust understanding of clinical practices and the associated technologies. You must be able to demonstrate excellent documenting, communication and project management skills.

You will be comfortable in a small company environment, appreciating the opportunities that it brings to demonstrate responsibility, and will understand the flexibility needed to meet the daily challenges.

To find out more:

If you’d like to know more about our company, please visit the website

If you’re interested in applying for this job, please send your C.V., including details of relevant qualifications and experience to:

Patent Output In Northern England (N8)

Impact Science has recently performed an analysis of the patent output from the N8 universities in Northern England, inspired by the current “Northern Futures” discussion (see

The results of our work shows that the N8 Cities have produced 2867 patents in the previous 10 years, of which 504 came from the N8 universities (Durham, Lancaster, Leeds, Liverpool, Manchester, Newcastle, Sheffield and York). By comparison, UK output during this period was 48506 patents, of which 2492 came from UK universities. This data provides some insight into the relative patenting activity in Northern England, but it also shows the significant contribution that non-university sources make to the intellectual property asset registers of our major cities.

Our analysis used the IDM Analytics ™ Platform, which has been developed by Impact Science and provides a rapid and comprehensive view of knowledge economy skills base capacity and assets, including scientific publications and patents.

Please contact Dr. Geoff Wainwright ( if you want to know more about this study, or if you are interested in finding out what the IDM Analytics ™ Platform can do.



Impact Science Research highlighted at Core Cities Summit

Knowledge Platform
Today, the question of devolution is high on the lips of everyone in the UK and whether Scotland stays in or out of the Union, the talk of devolution of powers has spread beyond it’s borders.

Last Friday, GVA ( hosted a Core Cities Summit that brought together a group of high-profile panelists from the public and private sectors to discuss the value that the UK’s core cities have to contribute towards economic growth. Whilst key themes around transport, policy, and finance were raised, a common theme was understanding the skills, expertise and unique offering those cities have that can propel forward business growth in the knowledge economy.

Impact Science have been working in partnership with GVA Ltd to map the research skills and expertise, and technologies being developed in our UK cities. Impact Science has developed a unique Knowledge Platform for rapidly identifying key strengths, differences and opportunities our core cities have in key industrial sectors. We are using data from a variety of public sources to, together with cutting edge visualisation techniques, simplify the presentation of tens of thousands of data points to answer those questions. We are defining the DNA of cities’ skills-base and enabling this to happen in minutes, not weeks.

This type of analysis is used by our clients to identify where global expertise lies in technology areas, or to provide an analysis of opportunities and future trends in a market segment, or even entire cities and countries. It is cutting through the complex language often associated with technology areas, and enabling key decision making to move forward based on a solid foundation of data and analysis.

Contact Geoff Wainwright to find out how our unique tools can empower you to make the right investment decision today.


2Bio Ltd. is pleased to announce that it has entered into a partnership with IBMC – Instituto de Biologia Molecular e Celular – to manage and commercialise its Intellectual property.

IBMC is a multidisciplinary research institution that brings together researchers working within the University of Porto, and affiliated hospitals, to produce a unique environment for research in the life sciences; it is recognised and funded by the Foundation for Science and Technology (FCT) of Portugal; the main Portuguese government body that funds science.

2Bio’s Impact Science Team will be deployed to evaluate technologies for their commercial potential, create commercialisation strategies and develop new business value for IBMC.
The work will also encompass all aspects of IP protection and management, integrating with IBMC’s own Tech Transfer Office.

The Impact Science Team has a strong track record of IP and market analysis in the life sciences sector, and has supported the creation of new business value for a wide range of international clients. The team has worked together for more than 10 years and draws on both science and business expertise in a wide range of disciplines.

Dr. Rhys Roberts, 2Bio’s co-founder said “this important strategic partnership gives 2Bio the opportunity to work seamlessly with the outputs of IBMC’s research excellence; we expect to identify and deliver valuable business outcomes for IBMC, and provide channels to reach global markets. We have been very impressed with what we have seen so far, from both the research and the leadership at the Institute”.

Professor Claudio Sunkel, IBMC Director, said “This partnership with 2Bio is the start of a new approach to explore Technology Transfer within our institute and we are all very excited to begin the process of detailed exploration of the technologies developed at our institute. IBMC’s main research interests are in the areas of Neurodegenerative diseases, Host-Pathogen Interactions and various aspects of Molecular and Cellular Biology related to Cell Division and Cancer.  We are confident that this partnership will be crucial in finding the appropriate routes for the commercialization of our human-related work, as well as our proven model organisms including mouse models”

President of the European Commission Visits Biocant

The President of the European Commission, José Manuel Durão Barroso, has officially opened the newest building of the park – UC- BIOTECH

The new building is dedicated to research and business training for the biotechnology sector of the Center for Neuroscience and Cell Biology and the University of Coimbra and it represents an investment of EUR 12.5million.

During the day the president toured Biocant Park and visited the companies and research laboratories based there, pointing out that Biocant is a very good example of the use of European structural funds.

President of the European Commission, José Manuel Durão Barroso with Dr. Carlos Faro of Biocant.

President of the European Commission, José Manuel Durão Barroso with Dr. Carlos Faro of Biocant.


Funding for Fusion Implants Ltd.

A company that helps dogs overcome lameless and restore mobility through 3D printing, has received a six-figure investment.

Fusion Implants, a biotech start-up company based in the UK, has recently received a six-figure investment to develop and market its products. The company has developed orthopaedic metal implants, using its patented 3-D printing technology, which provides much greater design freedom than conventional manufacturing techniques, and also allows them to combine solid and porous sections for optimum strength and biological performance. Their lead implant, which is for use in canine knee reconstructions, is already on the market and is being sold to veterinary practices.

The company is a synergy of  the skills and expertise of engineers – Dr. Dan Jones and Dr. Chris Sutcliffe, and vets –  Professor John Innes, Mr Rob Pettitt and Mr Ben Walton. Dr. Dan Jones, who is the general Manager of Fusion Implants said, “Our future plans include working closely with our veterinary surgeon customers to provide the next generation of animal implants. In particular, we will be working on a range of hip implants to suit specific breeds.“

Investment has been provided by The North West Fund for Venture Capital, managed by Enterprise Ventures. Fusion Implants will use the funding to roll out its current product, employ a design engineer and finance new product development. Rupture of the canine cranial cruciate ligament (CCL) remains the most common orthopaedic problem seen in veterinary practices around the world and can cause knee pain and lameness. CCL surgery involves a portion of bone being removed from the tibia to allow the restructuring of the angle of the knee joint, which is subsequently held in place by an implant. The Fusion Implants team have devised a way to manufacture high-performance veterinary implants from titanium using 3D printing, or additive manufacturing as it is also known. Fusion Implants’ technology allows the mass manufacture of porous titanium material, which allows the animal’s bone to grow into the implant, forming a natural bond and improving performance considerably.

The Impact Science team provided the commercial support for the start-up process, including market research, business planning and intellectual property advice. Dr. Rhys Roberts of Impact Science said “we are very pleased that this technology has moved up to the next stage, and that we were able to introduce the Fusion Implants team to Enterprise Ventures.


Polymer Membranes Can Improve New Drug Discovery

16 November 2012

Researchers at Singapore’s A*STAR Institute of Materials Research and Engineering (IMRE) have developed a remarkable new technology which promises to speed up the process of discovering vital new therapeutic drugs.

The inventors, Dr. Madhavan Nallani and his team, were recently recognised by the last Asian innovation Awards, held at the Four Seasons Hotel in Hong Kong, where host and former UK Prime Minister, Sir John Major, discussed the huge potential benefits of the invention with Dr. Nallani.

The invention allows polymers to be formed into structures that mimic natural cell membranes, and into which proteins can be inserted to represent the proteins found on real cells. This artificial system can be used as a very sophisticated laboratory model to understand how drugs interact with human cells in diseases such as Diabetes, Cancer or Parkinson’s Disease.

The process that is generally used by the pharmaceutical industry for finding and developing new drugs, uses real cells that are grown up in large-scale cell cultures, which are engineered to produce a new proteins on their membranes, to represent key elements that may be affected in a human disease condition. These proteins are called ‘receptors’. The cells are then exposed to large numbers of potential drugs to work out which ones stick to the ‘receptor’ and therefore could affect the human disease. By using this screening process, pharmaceutical companies hope to find the needle in the haystack, and develop these drugs into new medicines.

The problems with this approach are that engineering and producing large batches of cells is a lengthy process, and real cells also have a lot of their own natural receptors that can confuse the screening process. The IMRE artificial cell membranes are easier and cheaper to produce than real cells, so using this innovation, drug screening can be performed more quickly and cheaply than before, with the removal of background ‘noise’ caused by the myriad of other receptors found on real cells.

The team in Singapore are now developing the technology for commercial application, and expect to spin this out into a new business very soon. Impact Science have been engaged to manage the transition from the research laboratory to a commercial business, which will offer improved drug screening services to the global pharmaceutical industry.

Rhys Roberts of Impact Science said: “this is a very promising new technology that will be a game-changer in the drug discovery services market. We have been working with Dr. Nallani and his team for more than 2 years and together we have built firm foundations for a valuable new business”.

For further information, contact Dr Rhys Roberts on +44 151 795 4100.

Impact Science Works with UK Hospital Trust

1 September 2012 

The Royal Liverpool University and Broadgreen Hospitals NHS Trust (RLBUHT) has entered into a partnership with Impact Science to create and manage a framework for the Trust’s Intellectual Property.

The Royal Liverpool University Hospital is the largest hospital within the Trust, providing emergency, general and specialist treatment to patients, with more than 700 beds. The Hospital’s research and development portfolio is one of the largest portfolios of clinical research in the North West of England with over 400 clinical research projects covering many disease areas including cancer, gastroenterology, oral health, stroke, ophthalmology, infection and pharmacology.

The addition of capabilities to protect and manage the IP associated with this valuable research activity is a logical progression in the Trusts plans to grow its portfolio of innovative activities.

Under this new partnership, the Impact Science Team is evaluating the Trust’s current IP portfolio and implementing practical systems to both manage the current portfolio and uncover new IP owned by the Trust. Through this arrangement staff involved in research, development and innovation will have access to specialist support from the Impact Science Team, including guidance and training on IP issues, and support for commercialising inventions and innovations.

Jules West, Operational Director of Research Development and Innovation, said: “We are delighted to be working with Impact Science. They are helping us to really focus on commercialisation and intellectual property, which we haven’t been able to do effectively before. This specialist support is invaluable and will help us to grow our portfolio.”

Rhys Roberts of Impact Science said “we are very pleased to be working with RLUBHT, and recognise the huge potential of its clinical research portfolio to generate and add value to IP”.

For further information, contact Dr Rhys Roberts on +44 151 795 4100.